Short Interest in Sensus Healthcare, Inc. (NASDAQ:SRTS) Declines By 22.9%
Short Interest in Sensus Healthcare, Inc. (NASDAQ:SRTS) Declines By 22.9%
Sensus Healthcare, Inc. (NASDAQ:SRTS – Get Rating) was the recipient of a large decrease in short interest in the month of July. As of July 31st, there was short interest totalling 305,000 shares, a decrease of 22.9% from the July 15th total of 395,500 shares. Approximately 2.6% of the company's shares are sold short. Based on an average trading volume of 232,700 shares, the days-to-cover ratio is currently 1.3 days.
人口普查保健公司(納斯達克:SRTS-GET Rating)是7月份空頭股數銷量大幅下降的接受者。截至7月31日,空頭股數共有30.5萬股,比7月15日的39.55萬股減少了22.9%。該公司約2.6%的股票被賣空。以232,700股的平均成交量計算,目前的天數與回補比率為1.3天。
Wall Street Analysts Forecast Growth
華爾街分析師預測經濟增長
Separately, Maxim Group reiterated a "buy" rating and set a $14.00 target price on shares of Sensus Healthcare in a research note on Friday, May 6th.
另外,Maxim Group在5月6日(星期五)的一份研究報告中重申了“買入”評級,併為Scount Healthcare的股票設定了14.00美元的目標價。
Insider Buying and Selling at Sensus Healthcare
Scount Healthcare的內幕買賣
In other news, CEO Joseph C. Sardano sold 36,093 shares of the company's stock in a transaction dated Tuesday, August 9th. The stock was sold at an average price of $13.97, for a total transaction of $504,219.21. Following the sale, the chief executive officer now directly owns 1,294,200 shares in the company, valued at $18,079,974. The sale was disclosed in a document filed with the SEC, which is available at this link. In other Sensus Healthcare news, Director Samuel O'rear sold 10,022 shares of the stock in a transaction on Tuesday, August 9th. The shares were sold at an average price of $13.96, for a total transaction of $139,907.12. Following the completion of the transaction, the director now owns 163,548 shares in the company, valued at $2,283,130.08. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Joseph C. Sardano sold 36,093 shares of the firm's stock in a transaction dated Tuesday, August 9th. The shares were sold at an average price of $13.97, for a total transaction of $504,219.21. Following the completion of the sale, the chief executive officer now owns 1,294,200 shares in the company, valued at $18,079,974. The disclosure for this sale can be found here. In the last ninety days, insiders sold 75,114 shares of company stock worth $1,056,202. 16.36% of the stock is currently owned by company insiders.
在另一則新聞中,首席執行官約瑟夫·C·薩達諾在8月9日星期二的交易中出售了36,093股公司股票。該股以13.97美元的平均價格出售,總成交金額為504,219.21美元。出售後,首席執行官現在直接擁有1,294,200股公司股票,價值18,079,974美元。這筆交易是在提交給美國證券交易委員會的一份文件中披露的,可以通過以下鏈接獲得。在其他人口普查醫療方面的消息,董事塞繆爾·奧雷爾在8月9日星期二的一次交易中出售了10,022股該股。這些股票以13.96美元的平均價格出售,總成交金額為139,907.12美元。交易完成後,董事現在擁有該公司163,548股,價值2,283,130.08美元。這筆交易是在提交給美國證券交易委員會的一份文件中披露的,該文件可通過美國證券交易委員會網站獲得。此外,首席執行官約瑟夫·C·薩達諾在日期為8月9日(星期二)的交易中出售了36,093股公司股票。這些股票以13.97美元的平均價格出售,總成交金額為504,219.21美元。出售完成後,行政總裁現擁有該公司1,294,200股股份,價值18,079,974元。此次拍賣的披露信息可在此處找到。在過去90天裏,內部人士拋售了75,114股公司股票,價值1,056,202美元。16.36%的股份目前由公司內部人士持有。
Institutional Investors Weigh In On Sensus Healthcare
機構投資者參與人口普查醫療
Sensus Healthcare Stock Up 6.2 %
人口普查醫療保健類股上漲6.2%
Shares of Sensus Healthcare stock opened at $14.97 on Monday. The business has a 50-day moving average price of $9.63 and a 200 day moving average price of $9.32. Sensus Healthcare has a fifty-two week low of $3.21 and a fifty-two week high of $15.25. The firm has a market cap of $249.67 million, a P/E ratio of 9.91 and a beta of 0.78.
Scount Healthcare股票週一開盤報14.97美元。該業務的50日移動均線價格為9.63美元,200日移動均線價格為9.32美元。Scount Healthcare的52周低點為3.21美元,52周高位為15.25美元。該公司市值為2.4967億美元,市盈率為9.91倍,貝塔係數為0.78。
About Sensus Healthcare
關於人口普查醫療保健
(Get Rating)
(獲取評級)
Sensus Healthcare, Inc, a medical device company, manufactures and sells radiation therapy devices to healthcare providers worldwide. The company uses superficial radiation therapy (SRT), a low-energy X-ray technology in its portfolio of treatment devices. It offers SRT-100, a photon X-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating non-melanoma skin cancers, including basal cell and squamous cell skin cancers, as well as other skin conditions, such as keloids; and SRT-100 Vision, which provides the user with a SRT-tailored treatment planning application that integrates the embedded high frequency ultrasound imaging module, volumetric tumor analysis, beam margins planning, and dosimetry parameters.
Scount Healthcare,Inc.是一家醫療設備公司,向世界各地的醫療保健提供者製造和銷售放射治療設備。該公司在其治療設備組合中使用了表面放射治療(SRT),這是一種低能X射線技術。它提供SRT-100,這是一種光子X射線低能量表面放射治療系統,為患者提供治療非黑色素瘤皮膚癌,包括基底細胞和鱗狀細胞皮膚癌,以及瘢痕疙瘩等其他皮膚疾病的替代手術;以及SRT-100 Vision,為用户提供SRT量身定製的治療計劃應用程序,其中集成了嵌入式高頻超聲成像模塊、體積腫瘤分析、束流邊緣規劃和劑量學參數。
Featured Stories
專題報道
- Get a free copy of the StockNews.com research report on Sensus Healthcare (SRTS)
- Here is a Simple 4 Stock Portfolio that Can Outperform the Market
- Is AMC Entertainment Pulling a Fast One on the APEs?
- Here's How the Inflation Reduction Act Energizes Power Stock
- 2 Important Retail Stock Battles to Watch
- MarketBeat: Week in Review 8/8 – 8/12
- 免費獲取StockNews.com關於人口普查醫療保健(SRTS)的研究報告
- 以下是一個簡單的4只股票投資組合,它可以跑贏大盤
- AMC娛樂公司是在對猩猩採取快速行動嗎?
- 以下是《降低通脹法案》如何提振電力庫存
- 值得關注的兩場重要的零售股大戰
- MarketBeat:回顧中的一週2012-8-8
Receive News & Ratings for Sensus Healthcare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sensus Healthcare and related companies with MarketBeat.com's FREE daily email newsletter.
接收人口普查和醫療保健日報的新聞和評級-在下面輸入您的電子郵件地址,通過MarketBeat.com的免費每日電子郵件時事通訊接收最新新聞和分析師對Scount Healthcare及相關公司評級的每日摘要。
譯文內容由第三人軟體翻譯。